Skip to main content
. 2024 Jan 3;69:103027. doi: 10.1016/j.redox.2024.103027

Fig. 1.

Fig. 1

Safety of prolonged administration of PHAR in mice. A, evolution of weight during the weeks of treatment. B, blood glucose levels, under fed conditions, throughout the weeks of treatment. C, serum albumin, D, total serum protein. E, alkaline phosphatase (AP). F, alanine aminotransferase (ALT). G, aspartate aminotransferase (AST). Data are mean ± S.D. (n = 6). *p < 0.05; according to a Student's t-test. Animals in this experiment were 11-month-old at the beginning of a 4-week treatment.